Otsuka N, Hiraoka T, Miyauchi Y, Hasegawa Y, Aratake Y, Furusho N, Kinoshita A, Mochinaga M, Yamaguchi T, Togami K
Jpn J Antibiot. 1985 Sep;38(9):2673-82.
SM-4300, a newly developed human immunoglobulin preparation was evaluated in 24 patients with severe bacterial infections and the following results were obtained. The clinical efficacy was excellent in 4 cases, good in 7, fair in 5, poor in 3 and unknown in 5 with the effective rate of 57.9%. No serious side effect nor abnormalities in laboratory findings due to administration of SM-4300 were observed except 1 case with slight elevation of GOT and GPT.
对新研制的人免疫球蛋白制剂SM - 4300在24例严重细菌感染患者中进行了评估，结果如下。临床疗效为优的有4例，良的有7例，中平的有5例，差的有3例，不明的有5例，有效率为57.9%。除1例谷草转氨酶（GOT）和谷丙转氨酶（GPT）轻度升高外，未观察到因使用SM - 4300引起的严重副作用或实验室检查异常。
